Evolus, Inc. (NASDAQ:EOLS) Q1 2026 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus, Inc. for First Quarter Earnings Conference Call.
Evolus Inc. (EOLS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Walleye Capital Will England | 253,817 | $1,761,490 | 0.01% | |
| 2. | Winton Capital Management David Harding | 11,100 | $77,034 | 0% | |
| 3. | 512 | $10,240 | +62% | 0% | |
| 4. | 100 | $694 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.82 | 30,000 | $204,486.00 | 88,629 | 2025-08-15 | Filing | |
| $9.45 | 20,000 | $189,000.00 | 50,378 | 2025-06-09 | Filing | |
| $7.41 | 174,967 | $1,296,505.47 | 275,550 | 2023-08-15 | Filing | |
| $11.11 | 14,043 | $156,064.07 | 7,296,543 | 2021-08-13 | Filing | |
| $10.99 | 23,000 | $252,774.60 | 7,282,500 | 2021-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.75 | 3,119 | $14,815.25 | 427,423 | 2026-03-20 | Filing | |
| $4.75 | 13,669 | $64,929.12 | 604,700 | 2026-03-20 | Filing | |
| $4.89 | 116,720 | $570,562.38 | 618,369 | 2026-03-17 | Filing | |
| $4.89 | 29,996 | $146,629.45 | 430,542 | 2026-03-17 | Filing | |
| $7.15 | 10,539 | $75,361.23 | 354,388 | 2025-12-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,840,828 | $33,595,347 | 0% | |
| 2. | 1,697,294 | $11,779,220 | 0% | |
| 3. | 1,487,264 | $10,321,612 | 0.11% | |
| 4. | 1,289,888 | $8,951,823 | 0.44% | |
| 5. | 908,180 | $6,302,769 | 0.01% |
News See All
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Fourth Quarter and Full Year 2025 Earnings Conference Call.
Mizuho Lowers Price Target on Evolus, Inc. (EOLS) to $15, Maintains Outperform Rating
On February 4, Mizuho analyst Uy Ear lowered the firm’s price target on Evolus, Inc.
11 High Growth Micro-cap Stocks to Buy
Investing in stocks of companies with market values under $300 million, otherwise known as micro-cap stocks, offers a unique opportunity to get in early on fast-growing businesses.
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics
Evolus Inc. (NASDAQ:EOLS) is one of the stocks that will double in 2026.
20 Stocks That Will Double in 2026
On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC's 'Closing Bell Overtime' to discuss the potential for another bullish year, but with more volatility.
Evolus, Inc. (NASDAQ:EOLS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Third Quarter Earnings Conference Call.
Evolus, Inc. (NASDAQ:EOLS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for standing by. Welcome to Evolus' Second Quarter Earnings Conference Call.
Evolus, Inc. (EOLS): A Bull Case Theory
We came across a bullish thesis on Evolus, Inc. (EOLS) on Substack by Greg ┃The Elevator Pitch. In this article, we will summarize the bulls’ thesis on EOLS. Evolus, Inc.
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone. And thank you for standing by. Welcome to Evolus's First Quarter Earnings Conference Call. As a reminder, today's conference is being recorded and webcast live.
Hedge Fund Resource Center